Significance of coexpression of urokinase-type plasminogen activator, and matrix metalloproteinase 3 (stromelysin) and 9 (gelatinase B) in colorectal carcinoma

被引:38
|
作者
Inuzuka, K
Ogata, Y
Nagase, H
Shirouzu, K
机构
[1] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka 8300011, Japan
[2] Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London W6 8LH, England
关键词
uPA; MMP-3; MMP-9; colorectal carcinoma;
D O I
10.1006/jsre.2000.5952
中图分类号
R61 [外科手术学];
学科分类号
摘要
Our previous study showed that proMMP-9 was activated by MMP-3 directly, and that proMMP-3 was activated by plasmin, It was postulated that the proMMP-9 activation mechanism through the protease-protease cascade existed even in vivo. The purpose of the present study was to clarify the clinical significance of the combined expression of MMP-9, MMP-3, and urokinase-type plasminogen activator (uPA) in colorectal cancer, and the role of MMP-3 or uPA expression as an activator for MMP-9. The expression of both MMP-9 and uPA was found to be correlated with liver metastasis, and with survival rate. The coexpression of MMP-9 and uPA by tumor cells was also significantly correlated with postoperative hepatic recurrence and survival rate. MMP-9 tended to be coexpressed with uPA, and was consistently associated with MMP-3 localized at the tumor-invasive front with inflammatory cells such as monocyte-macrophages, In gelatin zymography, the MMP-9 active form tended to be identified in the tumors that coexpressed both MMP-9 and uPA We concluded that coexpression of MMP-9 and uPA in tumor tissues might be a useful predictive factor for postoperative survival and hepatic metastasis. The following activation mechanism for proteinase might occur: uPA coexpressed with MMP-9 activated plasminogen, and plasmin activated proMMP-3, which was secreted depending upon inflammatory infiltration, and then MMP-3 activated proMMP-9, resulting in colorectal cancer progression and metastasis. (C) 2000 Academic Press.
引用
收藏
页码:211 / 218
页数:8
相关论文
共 50 条
  • [31] Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer
    A Knoop
    PA Andreasen
    JA Andersen
    S Hansen
    A-V Lænkholm
    ACW Simonsen
    J Andersen
    J Overgaard
    C Rose
    British Journal of Cancer, 1998, 77 : 932 - 940
  • [32] Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in Gouty arthritis of the knee
    Chu, SC
    Yang, SF
    Lue, KH
    Hsieh, YS
    Hsiao, TY
    Lu, KH
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 311 - 317
  • [33] Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas
    Fujii, T
    Obara, T
    Tanno, S
    Ura, H
    Kohgo, Y
    HEPATO-GASTROENTEROLOGY, 1999, 46 (28) : 2299 - 2308
  • [34] Urokinase-type plasminogen activator, plasminogen activator inhibitor type 1 and cathepsin D: Analysis of their prognostic significance in squamous cell carcinoma of the head and neck
    Strojan, P
    Budihna, M
    Smid, L
    Vrhovec, I
    Skrk, J
    ANTICANCER RESEARCH, 2000, 20 (5C) : 3975 - 3981
  • [35] Aspirin Inhibits IKK-β-mediated Prostate Cancer Cell Invasion by Targeting Matrix Metalloproteinase-9 and Urokinase-Type Plasminogen Activator
    Shi, Chongjun
    Zhang, Nini
    Feng, Yang
    Cao, Jiewei
    Chen, Xuyi
    Liu, Bin
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2017, 41 (04) : 1313 - 1324
  • [36] Regulation of proteinases during mouse peri-implantation development: urokinase-type plasminogen activator expression and cross talk with matrix metalloproteinase 9
    Martinez-Hernandez, M. G.
    Baiza-Gutman, L. A.
    Castillo-Trapala, A.
    Armant, D. Randall
    REPRODUCTION, 2011, 141 (02) : 227 - 239
  • [37] Regulation of collagenase, stromelysin, and urokinase-type plasminogen activator in primary pterygium body fibroblasts by inflammatory cytokines
    Soloman, A
    Li, DQ
    Lee, SB
    Tseng, SCG
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2000, 41 (08) : 2154 - 2163
  • [38] Combined evaluation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression in gastric carcinoma
    Maeda, K
    Chung, YS
    Sawada, T
    Ogawa, Y
    Onoda, N
    Nakata, B
    Kato, Y
    Sowa, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (03) : 499 - 503
  • [39] Urokinase-type plasminogen activator and metalloproteinase-2 are related to the carotid atherosclerosis in haemodialysis patients
    Pawlak, D.
    Pawlak, K.
    Mysliwiec, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 107 - 107
  • [40] Significance of Soluble Urokinase-type Plasminogen Activator Receptor in Patients with Coronary Heart Disease
    Zheng, Zhenda
    Cheng, Cailian
    Liu, Dinghui
    Song, Zhiming
    Chen, Lin
    Qian, Xiaoxian
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (16) : C144 - C144